Everolimus, an inhibitor of the mammalian target rapamycin (mTOR) and octreotide improves progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, say researchers at The University of Texas MD Anderson Cancer Center. ...Read More